Journal article
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
J Desai, S Deva, JS Lee, CC Lin, CJ Yen, Y Chao, B Keam, M Jameson, MM Hou, YK Kang, B Markman, CH Lu, KM Rau, KH Lee, L Horvath, M Friedlander, A Hill, S Sandhu, P Barlow, CY Wu Show all
Journal for Immunotherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2020
Abstract
Background The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to Fc 3R on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors. Methods Patients (aged ≥18 years) ..
View full abstract